Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- TS-1 Generics Now Have Same Indications as Originator
May 25, 2017
- Sensor-Embedded Abilify Resubmitted to FDA
May 25, 2017
- Ninlaro Makes Japan Debut, Mundesine Now Also Available
May 25, 2017
- FY2016 Sales Dip for 27 Japan Makers, Second-Tier/Mid-Sized Firms Fare Well: Jiho Tally
May 24, 2017
- 4 Major Distributors’ Wholesale Biz Sinks on Hep C Pullback, Price Revision
May 23, 2017
- Lantus XR Shows Efficacy in Japan Outcome Study: Interim Report
May 23, 2017
- EMA Accepts Application for Fujifilm Kyowa Kirin’s Humira Biosimilar
May 23, 2017
- Ethical Drug Sales Down 4.4% in March: Crecon
May 22, 2017
- Japan NDA Filed for Januvia-Suglat Combination
May 22, 2017
- MHLW OKs Xalkori for ROS1-Positive NSCLC; Zosyn, Kyprolis for Add’l Use
May 19, 2017
- Ogeda Acquisition Completed: Astellas
May 18, 2017
- Opdivo Ranks 2nd in FY2016 Japan Sales Ranking after Harvoni: QuintilesIMS
May 17, 2017
- Aspen Japan to Expand Detailing System with Business Transfer from AZ
May 17, 2017
- Otsuka Gets Japan Rights to Teva’s Migraine Med
May 16, 2017
- Fujifilm, FunPep Join Hands to Create Middle-Molecule Antiviral for HPV
May 16, 2017
- Otsuka to Build Its 6th Drug Factory in Japan, Launch Slated for 2020
May 16, 2017
- Otsuka, Hiroshima Univ. Spinout to Collaborate on CNS Cell Therapies
May 16, 2017
- Seikagaku, Ono to Link Up on Osteoarthritis Treatment
May 16, 2017
- Takeda to Split Part of Research Biz Into New Subsidiary
May 16, 2017
- Suzuken Embarking on Organizational Reforms to Eliminate “High-Cost Structure,” Improve SGA Cost Ratio
May 16, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…